Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-03
2007-07-03
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S123000
Reexamination Certificate
active
10764229
ABSTRACT:
Compounds represented by Formula (I):or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition.
REFERENCES:
patent: 4284629 (1981-08-01), Grohe et al.
patent: 5321029 (1994-06-01), Maschler et al.
patent: 5631256 (1997-05-01), Demuth, Jr. et al.
patent: 5753666 (1998-05-01), Beasley et al.
patent: 5817670 (1998-10-01), Takayama et al.
patent: 6306869 (2001-10-01), Flockerzi
patent: 6677351 (2004-01-01), Li et al.
patent: 2006/0058316 (2006-03-01), Dube et al.
patent: WO 99/07704 (1999-02-01), None
patent: WO 02/09823 (2002-11-01), None
patent: WO 02/094823 (2002-11-01), None
Houslay, et al., “Phosphodiesterase-4 as a therapeutic target”, Drug Discovery Today, 10 (22), Nov. 2005, pp. 1503-1519.
Meijsing, et al., “Effects of the phosphodiestease-IV inhibitor EMD 95832/3 on tumour growth . . . ”, Cancer Letters, 188 (2002), pp. 53-58.
Ochi, et al., “Necessity of intracellular cyclic AMP in inducing gastric acid secretion . . . ”, Life Sciences, 77 (205), pp. 2040-2050.
Kayanoki, et al., “The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor . . . ”, Biochemical and Biophysical research communications, vol. 238, issue 2, Sep. 18, 1997, abstract.
Vlachopoulos, et al., “Type 5 phosphodiesterase inhibition by sildenafil . . . ”, American journal of hypertension, vol. 17, issue 11, Nov. 2004, abstract.
Compton, et al., “Cilomilast, a Selective Phosphodiesterase-4 Inhibitor for Treatment of Patients with Chronic Obstructive Pulmonary disease: A Randomised, Dose-Ranging Study”, The Lancet, vol. 358, pp. 265-270, 2001.
Rabe, et al., “Roflumilast-An Oral Anti-Inflammatory Treatment For Chronic Obstructive Pulmonary Disease: A Randomised Controlled Trial”, The Lancet, vol. 366, pp. 563-571, 2005.
Rose, et al., “Phosphodiesterase Inhibitors for Cognitive Enhancement”, Current Pharmaceutical Design, vol. 11, pp. 3329-3334, 2005.
Aspiotis Renee
Dube Daniel
Dube Laurence
Gallant Michel
Girard Yves
Ayler Sylvia A.
Krovatin William
Merck Frosst Canada Ltd.
Rahmani Niloofar
Seaman Margaret D.
LandOfFree
4-oxo-1-(3-substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-oxo-1-(3-substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-oxo-1-(3-substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3785322